sarepta - Search News

Order byBest matchMost fresh

News

Sarepta shares rebound

· 1h · on MSN

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

Continue reading

Sarepta can begin shipping Elevidys therapy after FDA reverses pause; stock soars.

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

4hon MSN

Sarepta Soars After FDA Says Some Patients Can Get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...

5h

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...

3h

Stock Movers: Sarepta, UPS, Whirlpool

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Business Wire1d

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

1don MSN

Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.

The selloff came after the U.S. Food and Drug Administration said late Friday that it was probing the death of an 8-year-old ...

Explore more

Duchenne muscular dystrophy

Food and Drug Administration

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Feedback
Privacy
Terms